During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
|Videos|March 29, 2018
Treatment of NSCLC With Uncommon EGFR Mutations
Treatment of NSCLC With Uncommon EGFR Mutations
Advertisement
- A female patient, Chinese descent, aged 66, is referred from primary care with persistent cough, sputum with blood, shortness of breath and chest pain
- History
- Never smoked
- Recurrent bronchitis over past 5 years
- Has never been screened for lung cancer (by radiography or low-dose CT [LDCT])
- Hypertension controlled on HCTZ; no diabetes, renal impairment
- Family history
- Grew up in China, moved to US at age 29; married for 30 years
- Grew up in family with heavy smokers
- Husband is current smoker
- LDCT reveals multiple tumors in left lung with pleural metastases
- Biopsy reveals non-small cell lung cancer
- Molecular analysis:
- EGFRmutation: G719X
- Negative forALKrearrangement
- Wild-typeKRAS
- The patient was started on afatinib, 40 mg once daily
- After one month on therapy, she reported having rather severe diarrhea (5 times/day)
- Treatment was discontinued, then re-started treatment at 30 mg/day
Advertisement
Related to this article
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
2
Durability of PFS and OS Benefit vs. Historical Control
3
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
4
Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer
5